Detection of androst-4-ene-3,6,17-trione (6-OXO®) and its metabolites in urine by gas chromatography-mass spectrometry in relation to doping analysis

被引:25
作者
Van Thuyne, W
Van Eenoo, P
Mikulciková, P
Deventer, K
Delbeke, FT
机构
[1] Univ Ghent, Fac Med & Hlth Sci, Dept Clin Biol Microbiol & Immunol, Doping Control Lab, B-9052 Zwijnaarde, Belgium
[2] Univ Pardubice, Fac Chem Technol, Dept Analyt Chem, CZ-35210 Pardubice, Czech Republic
关键词
6-OXO; androst-4-ene-3,6,17-trione; androst-4-ene-6 alpha-ol-3,17-dione; doping; nutritional supplement;
D O I
10.1002/bmc.496
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The metabolism and excretion of androst-4-ene-3,6,17-trione after administration of the 'nutritional' supplement 6-OXO (R) was investigated by gas chromatography-mass spectrometry (GC-MS) in full-scan mode. The parent drug androst-4-ene3,6,17-trione and androst-4-ene-6 alpha,17 beta-diol-3-one and androst-4-ene-6 alpha-ol-3,17-dione were detected in the post-administration urine samples. Because androst-4-ene-3,6,17-trione is an anabolic steroid and an aromatase inhibitor, this substance is regarded as a doping agent. Hence, a selective and sensitive GC-MS method in selected ion monitoring mode for the detection of the TMS-enol-TMS-ether derivatives of these substances was developed and validated for doping control purposes. The limit of detection (LOD) of the investigated compounds ranged from 5 to 10 ng/mL. Using this method, the detection time for androst-4-ene-3,6,17-trione and androst-4-ene-6 alpha,17 beta-diol-3-one was 24 h, while androst-4-ene-6 alpha-ol-3,17-dione could be detected up to 37 It after administration of the dose recommended by the manufacturer. Copyright (c) 2005 John Wiley & Sons, Ltd.
引用
收藏
页码:689 / 695
页数:7
相关论文
共 25 条
[1]   Testing for natural and synthetic anabolic agents in human urine [J].
Ayotte, C ;
Goudreault, D ;
Charlebois, A .
JOURNAL OF CHROMATOGRAPHY B, 1996, 687 (01) :3-25
[2]  
BRIGGS M H, 1970, P424
[4]   Prohormones and sport [J].
Delbeke, FT ;
Van Eenoo, P ;
Van Thuyne, W ;
Desmet, N .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2002, 83 (1-5) :245-251
[5]  
Eurachem, 1998, FITN PURP AN METH LA, P61
[6]  
HARVEY HA, 1982, CANCER RES S, V42, pS3261
[7]   Evaluation of human hepatocyte incubation as a new tool for metabolism study of androstenedione and norandrostenedione in a doping control perspective [J].
Lévesque, JF ;
Gaudreault, M ;
Houle, R ;
Chauret, N .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2002, 780 (01) :145-153
[8]  
LEVESQUE JF, 1999, RECENT ADV DOPING AN, P169
[9]  
MARECK U, 2004, RECENT ADV DOPING AN, P91
[10]   STUDIES ON AROMATASE INHIBITION WITH 4-ANDROSTENE-3,6,17-TRIONE - ITS 3-BETA-REDUCTION AND TIME-DEPENDENT IRREVERSIBLE BINDING TO AROMATASE WITH HUMAN PLACENTAL MICROSOMES [J].
NUMAZAWA, M ;
TSUJI, M ;
MUTSUMI, A .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1987, 28 (03) :337-344